User Image Cart Icon 0 Search Image

Piper Longum

  1. Overview of the therapeutic potential of piplartine (piperlongumine)
  2. Piperlongumine suppresses proliferation of human oral squamous cell carcinoma through cell cycle arrest, apoptosis and senescence
  3. Synthesis, cellular evaluation, and mechanism of action of Piperlongumine analogs
  4. Alkaloids of Piper longum Linn—I: Structure and synthesis of Piperlongumine and piperlonguminine
  5. Piperlongumine induces autophagy by targeting p38 signaling
  6. Drug-repositioning screening identified Piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer
  7. Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death
  8. Antiplatelet activities of newly synthesized derivatives of piperlongumine
  9. Piperlongumine induces inhibition of the ubiquitin–proteasome system in cancer cells
  10. Synthesis and molecular structure of piplartine (= piperlongumine)
  11. Activation of ERK signaling and induction of colon cancer cell death by piperlongumine
  12. Discovery of Piperlongumine as a potential novel lead for the development of senolytic agents
  13. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells
  14. Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel in human ovarian cancer cells
  15. Piperlongumine inhibits atherosclerotic plaque formation and vascular smooth muscle cell proliferation by suppressing PDGF receptor signaling
  16. Piperlongumine inhibits NF‐κB activity and attenuates aggressive growth characteristics of prostate cancer cells
  17. Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation
  18. Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer
  19. Piperlongumine, a constituent of Piper longum L., inhibits rabbit platelet aggregation as a thromboxane A2 receptor antagonist
  20. Piperlongumine inhibits proliferation and survival of Burkitt lymphoma in vitro
  21. Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer
  22. … induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with Piperlongumine in gastric cancer
  23. Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells
  24. Inhibition of Aflatoxin B~ 1 Biosynthesis by Piperlongumine Isolated from Piper longum L
  25. Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP
  26. Piperlongumine induces pancreatic cancer cell death by enhancing reactive oxygen species and DNA damage
  27. Synthesis and biological evaluation of Piperlongumine derivatives as potent anti-inflammatory agents
  28. Synthesis of Piperlongumine analogues and discovery of nuclear factor erythroid 2-related factor 2 (Nrf2) activators as potential neuroprotective agents
  29. Piperlongumine inhibits migration of glioblastoma cells via activation of ROS-dependent p38 and JNK signaling pathways
  30. Development and mechanism investigation of a new Piperlongumine derivative as a potent anti-inflammatory agent
  31. Design, synthesis and biological activity of Piperlongumine derivatives as selective anticancer agents
  32. Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway
  33. Piperlongumine for enhancing oral bioavailability and cytotoxicity of docetaxel in triple-negative breast cancer
  34. Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells
  35. Designing piperlongumine-directed anticancer agents by an electrophilicity-based prooxidant strategy: a mechanistic investigation
  36. Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38/JNK pathways
  37. Biosynthesis of piperlongumine
  38. Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells
  39. Design and synthesis of a C7-aryl Piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties
  40. Piperlongumine and immune cytokine TRAIL synergize to promote tumor death
  41. Biodegradable nanoassemblies of Piperlongumine display enhanced anti-angiogenesis and anti-tumor activities
  42. Piperlongumine inhibits lung tumor growth via inhibition of nuclear factor kappa B signaling pathway
  43. Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity
  44. Heme oxygenase-1 determines the differential response of breast cancer and normal cells to piperlongumine
  45. Piperlongumine (piplartine) and analogues: Antiproliferative microtubule-destabilising agents
  46. Redox-directed cancer therapeutics: Taurolidine and Piperlongumine as broadly effective antineoplastic agents
  47. Piperlongumine induces cell death through ROS-mediated CHOP activation and potentiates TRAIL-induced cell death in breast cancer cells
  48. Piperlongumine chemosensitizes tumor cells through interaction with cysteine 179 of IκBα kinase, leading to suppression of NF-κB–regulated gene products
  49. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma
  50. Piperlongumine reverses doxorubicin resistance through the PI3K/Akt signaling pathway in K562/A02 human leukemia cells
  51. Structural and biochemical analyses reveal the mechanism of glutathione S-transferase Pi 1 inhibition by the anti-cancer compound piperlongumine
  52. Piperlongumine induces reactive oxygen species (ROS)-dependent downregulation of specificity protein transcription factors
  53. Piperlongumine restores the balance of autophagy and apoptosis by increasing BCL2 phosphorylation in rotenone-induced Parkinson disease models
  54. Metabolic profile and safety of piperlongumine
  55. Preformulation studies on piperlongumine
  56. Piperlongumine suppresses growth and sensitizes pancreatic tumors to gemcitabine in a xenograft mouse model by modulating the NF-kappa B pathway
  57. Piperlongumine selectively suppresses ABC-DLBCL through inhibition of NF-κB p65 subunit nuclear import
  58. Historical spice as a future drug: therapeutic potential of piperlongumine
  59. Antibacterial activity of Piperlongumine an alkaloid isolated from methanolic root extract of Piper Longum L
  60. Piperlongumine inhibits gastric cancer cells via suppression of the JAK1, 2/STAT3 signaling pathway
  61. Preparation of piperlongumine-loaded chitosan nanoparticles for safe and efficient cancer therapy
  62. Piperlongumine induces G2/M phase arrest and apoptosis in cholangiocarcinoma cells through the ROS-JNK-ERK signaling pathway
  63. Methods for the treatment of cancer using Piperlongumine and Piperlongumine analogs
  64. Piperlongumine suppresses dendritic cell maturation by reducing production of reactive oxygen species and has therapeutic potential for rheumatoid arthritis
  65. Synthesis and antileukemic activities of Piperlongumine and HDAC inhibitor hybrids against acute myeloid leukemia cells
  66. Rapid validated HPTLC method for estimation of piperine and Piperlongumine in root of Piper longum extract and its commercial formulation
  67. Piperlongumine as a potential activator of AMP-activated protein kinase in HepG2 cells
  68. Piperlongumine alleviates lupus nephritis in MRL-Fas (lpr) mice by regulating the frequency of Th17 and regulatory T cells
  69. Horner–Wadsworth–Emmons approach to Piperlongumine analogues with potent anti-cancer activity
  70. Elevated PRC1 in gastric carcinoma exerts oncogenic function and is targeted by Piperlongumine in a p53‐dependent manner
  71. JNK signaling pathway is involved in piperlongumine‑mediated apoptosis in human colorectal cancer HCT116 cells
  72. Proteomic evaluation on antiplatelet activity of Piperlongumine derived from Piper longum
  73. Developing piperlongumine-directed glutathione S-transferase inhibitors by an electrophilicity-based strategy
  74. The crystal and molecular structure of N-(3,4,5-trimethoxycinnamoyl)-Δ3-piperidine-2-one, an amide alkaloid (piperlongumine), C17H19NO5
  75. Piperlongumine induces gastric cancer cell apoptosis and G2/M cell cycle arrest both in vitro and in vivo
  76. Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1
  77. Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells
  78. Piperlongumine downregulates the expression of HER family in breast cancer cells
  79. Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance
  80. Design, synthesis and pharmacological evaluation of novel Piperlongumine derivatives as potential antiplatelet aggregation candidate
  81. Impact of DNA repair pathways on the cytotoxicity of Piperlongumine in chicken DT40 cell-lines
  82. Preventive potentials of Piperlongumine and a Piper longum extract against stress responses and pain
  83. Synthesis and evaluation of N-heteroaromatic ring-based analogs of Piperlongumine as potent anticancer agents
  84. Simultaneous determination of piperine and Piperlongumine in Piper longum by HPLC
  85. Identification of novel ROS inducer by merging the fragments of Piperlongumine and dicoumarol
  86. Senolytic activity of Piperlongumine analogues: Synthesis and biological evaluation
  87. Novel non-trimethoxylphenyl Piperlongumine derivatives selectively kill cancer cells
  88. Piperlongumine suppresses proliferation of human oral squamous cell carcinoma through cell cycle arrest, apoptosis and senescence
  89. Piperlongumine exerts cytotoxic effects against cancer cells with mutant p53 proteins at least in part by restoring the biological functions of the tumor …
  90. Coloaded nanoparticles of paclitaxel and Piperlongumine for enhancing synergistic antitumor activities and reducing toxicity
  91. Piperlongumine derived cyclic sulfonamides (sultams): Synthesis and in vitro exploration for therapeutic potential against HeLa cancer cell lines
  92. Two-stage nanoparticle delivery of Piperlongumine and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) anti-cancer therapy
  93. Transcriptome analysis of piperlongumine-treated human pancreatic cancer cells reveals involvement of oxidative stress and endoplasmic reticulum stress pathways
  94. Synthetic analogue of the natural product Piperlongumine as a potent inhibitor of breast cancer cell line migration
  95. Using Sensors and Generators of H2O2 to Elucidate the Toxicity Mechanism of Piperlongumine and Phenethyl Isothiocyanate
  96. Piperlongumine activates Sirtuin1 and improves cognitive function in a murine model of Alzheimer’s disease
  97. Keto-enol-based modification on Piperlongumine to generate a potent Cu (II) ionophore that triggers redox imbalance and death of HepG2 cells
  98. Piperlongumine attenuates collagen-induced arthritis via expansion of myeloid-derived suppressor cells and inhibition of the activation of fibroblast-like …
  99. Piperlongumine attenuates experimental autoimmune encephalomyelitis through inhibition of NF-kappaB activity
  100. Piperlongumine (piplartine) as a lead compound for anticancer agents–Synthesis and properties of analogues: A mini-review
  101. Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis
  102. Piperlongumine potentiates the effects of gemcitabine in in vitro and in vivo human pancreatic cancer models
  103. Piperlongumine inhibits neuroinflammation via regulating NF-κB signaling pathways in lipopolysaccharide-stimulated BV2 microglia cells
  104. Hypoxia potentiates the cytotoxic effect of Piperlongumine in pheochromocytoma models
  105. Antileukemic effects of Piperlongumine and alpha lipoic acid combination on Jurkat, MEC1 and NB4 cells in vitro
  106. Piperlongumine blocks JAK2-STAT3 to inhibit collagen-induced platelet reactivity independent of reactive oxygen species
  107. Novel ligustrazine-based analogs of Piperlongumine potently suppress proliferation and metastasis of colorectal cancer cells in vitro and in vivo
  108. Long lasting preventive effects of Piperlongumine and a Piper longum extract against stress triggered pathologies in mice
  109. Effect of Piperlongumine on drug resistance reversal in human retinoblastoma HXO-RB44/VCR and SO-Rb50/CBP cell lines
  110. Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization
  111. Specific 5-hydroxylation of Piperlongumine by Beauveria bassiana ATCC 7159
  112. Piperlongumine inhibits the proliferation, migration and invasion of fibroblast-like synoviocytes from patients with rheumatoid arthritis
  113. Piperlongumine decreases cognitive impairment and improves hippocampal function in aged mice
  114. Experimental study of Piperlongumine inducing apoptosis of human breast adenoma MDA-MB-231 cells
  115. Piperlongumine decreases cell proliferation and the expression of cell cycle-associated proteins by inhibiting Akt pathway in human lung cancer cells
  116. Piperlongumine inhibits cancer stem cell properties and regulates multiple malignant phenotypes in oral cancer
  117. Piperlongumine-induced phosphatidylserine translocation in the erythrocyte membrane
  118. Piperlongumine inhibits TGF-β-induced epithelial-to-mesenchymal transition by modulating the expression of E-cadherin, Snail1, and Twist1
  119. Exploiting mitochondrial and oxidative vulnerabilities with a synthetic analog of pancratistatin in combination with Piperlongumine for cancer therapy
  120. Leishmanicidal effects of Piperlongumine (piplartine) and its putative metabolites
  121. Piperlongumine improves lipopolysaccharide-induced amyloidogenesis by suppressing NF-KappaB pathway
  122. Nanoparticle-encapsulated piperine and Piperlongumine inhibit breast cancer cell growth and metastatic activity
  123. Piperlongumine B and analogs are promising and selective inhibitors for acetylcholinesterase
  124. Correction: Piperlongumine Blocks JAK2-STAT3 to Inhibit Collagen-Induced Platelet Reactivity Independent of Reactive Oxygen Species
  125. Piperlongumine Induces Apoptosis in Human Melanoma Cells Via Reactive Oxygen Species Mediated Mitochondria Disruption
  126. Piperlongumine induces autophagy in biliary cancer cells via reactive oxygen species-activated Erk signaling pathway
  127. The synergistic effects of oxaliplatin and Piperlongumine on colorectal cancer are mediated by oxidative stress
  128. Piperlongumine Induces Apoptosis in Colorectal Cancer HCT 116 Cells Independent of Bax, p21 and p53 Status
  129. Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways
  130. Simultaneous quantitation of piperine and Piperlongumine in the fruit of Piper longum Linn. by validated high-performance thin-layer chromatography-densitometric …
  131. Redox-and pH-Responsive Nanoparticles Release Piperlongumine in a Stimuli-Sensitive Manner to Inhibit Pulmonary Metastasis of Colorectal Carcinoma Cells
  132. Simultaneous quantification of Piperlongumine and piperine in traditional polyherbal formulation using validated HPLC method
  133. An investigation into the interaction between piplartine (piperlongumine) and human serum albumin
  134. Cancer-specific pro-oxidant therapy using low-toxic polypeptide micelles encapsulating piperlongumine
  135. Piperlongumine potentiates the antitumor efficacy of oxaliplatin through ROS induction in gastric cancer cells
  136. Piperlongumine analogue L50377 induces pyroptosis via ROS mediated NF-κB suppression in non-small-cell lung cancer
  137. Piperlongumine-induced nuclear translocation of the FOXO3A transcription factor triggers BIM-mediated apoptosis in cancer cells
  138. Spectroscopic investigation of the anticancer alkaloid Piperlongumine binding to human serum albumin from the viewpoint of drug delivery
  139. Development of a method for quantitative determination of the cytotoxic agent piplartine (piperlongumine) in multiple skin layers
  140. Piperlongumine derivative, CG-06, inhibits STAT3 activity by direct binding to STAT3 and regulating the reactive oxygen species in DU145 prostate carcinoma cells
  141. Computational Analysis of Piperlongumine and Piperlongumine Analogs
  142. P1 Piperlongumine inhibits growth potential of gastric cancer cells by targeting PI3K/Akt/mTOR signaling pathway
  143. Microtubule-Destabilising Actions of Piperlongumine and Analogues
  144. Metabolic profile and safety of piperlongumine.
  145. Piperlongumine suppressed osteoclastogenesis in RAW264. 7 macrophages
  146. Effects of Piperlongumine on cognitive function and amyloid pathology
  147. Piperlongumine Enhances Chemotherapy-Induced Pancreatic Cancer Cell Death
  148. Survivin promotes Piperlongumine resistance in ovarian cancer
  149. Piperlongumine, a novel treatment option to overcome BRAF inhibitor resistance in melanoma
  150. Mechanisms of Piperlongumine-Induced Cancer Cell Death
  151. Piperlongumine attenuates IL-1β-induced inflammatory response in chondrocytes
  152. Piperlongumine as anticancer agent: The story so far about killing many birds with one stone.
  153. Discovery Of Piperlongumine Derivatives As Anti-Leukemic And Anti-Prostate Cancer Agents
  154. Piperlongumine selectively suppresses ABC-DLBCL through inhibition of NF-κB p65 subunit nuclear import
  155. Piperlongumine inhibits angiotensin II‐induced extracellular matrix expression in cardiac fibroblasts
  156. Inhibition of Piperlongumine on platelet aggregation and blood coagulation for children in vitro study
  157. Abstract B023: Identification and biochemical validation of Piperlongumine as a potent therapeutic against neuroendocrine prostate cancer
  158. Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression
  159. Piperlongumine produces antidepressant-like effects in rats exposed to chronic unpredictable stress
  160. Differential cytotoxic effects of Piperlongumine analogues and their radiotherapeutic response in breast cancer
  161. Hybrid anticancer drugs: Synthesis of Combretastatin-Piperlongumine fused analogs with mutant p53 reactivation and antimicrotubule properties
  162. Piperlongumine (PPLGM) has potent tumor-radiosensitizing properties in a mouse model of lung cancer
  163. Development of a method for quantitative determination of the cytotoxic agent piplartine (piperlongumine) in multiple skin layers
  164. Hybrid anticancer drugs: Synthesis of a combretastatin-Piperlongumine analog with mutant p53 reactivation and antimicrotubule properties
  165. Inhibition of STAT-3 by Piperlongumine induces anoikis, prevents tumor formation in pancreatic cancer in vitro and in vivo
  166. Stimuli responsive nanoparticles release Piperlongumine to inhibit pulmonary metastasis of colorectal carcinoma cells
  167. Effect and Underlying Mechanism of Piperlongumine on Proliferation and Apoptosis of Human Gastric Cancer Cell Line MKN45
  168. Computational drug repositioning and biochemical validation of Piperlongumine as a potent therapeutic agent for neuroendocrine prostate cancer
  169. On the inhibition mechanism of glutathione transferase P1 by piperlongumine. Insight from theory
  170. Inhibition of STAT-3 by Piperlongumine induces anoikis in melanoma cells in vitro and blocks tumor formation potential in vivo.
  171. Antimicrobial and Synergistic Effects of Commercial Piperine and Piperlongumine in Combination with Conventional Antimicrobials
  172. PD37-10 BIOCHEMICAL VALIDATION OF Piperlongumine AS A POTENT THERAPEUTIC AGAINST NEUROENDOCRINE PROSTATE CANCER
  173. Abstract B59: The combined effects of piperlongumine, vitamin C, and vitamin D on Caenorhabditis elegans and Volvox carteri
  174. Piperlongumine and some of its analogs inhibit selectively the human immunoproteasome over the constitutive proteasome
  175. Piperlongumine reduces ovalbumin‑induced asthma and airway inflammation by regulating nuclear factor‑κB activation
  176. Liposomal Nanoformulation of Piperlongumine for Improved Aqueous Solubility and Enhanced Anti-tumour Activity In-vitro
  177. Abstract A86: Piperlongumine enhances the efficacy of gemcitabine in pancreatic cancer cells in vitro and in vivo
  178. Piperlongumine Induces Apoptosis of Lung Cancer Cells via the PI3K/Akt/mTOR Signaling Pathways
  179. Naturally occurring Piper plant amides potential in agricultural and pharmaceutical industries: perspectives of piperine and piperlongumine
  180. Loading of Piperlongumine to liposomes after complexation with β-cyclodextrin and its effect on viability of colon and prostate cancer cells
  181. Piperlongumine-Eluting Gastrointestinal Stent Using Reactive Oxygen Species-Sensitive Nanofiber Mats for Inhibition of Cholangiocarcinoma Cells
  182. Piperlongumine, a novel TrxR1 inhibitor, induces apoptosis in hepatocellular carcinoma cells by ROS-mediated ER stress
  183. The effect of Piperlongumine on endothelial and lung adenocarcinoma cells with regulated expression of profilin-1
  184. Part A. Efficient synthesis of Piperlongumine Part B. Synthesis and Evaluation of Pyrenyl-appended Calix [4] triazole
  185. Details of the cooperative binding of Piperlongumine with rat serum albumin obtained by spectroscopic and computational analyses
  186. Design and Green Synthesis of Piperlongumine Analogs and Their Antioxidant Activity against Cerebral Ischemia-Reperfusion Injury
  187. Piperlongumine Achieves Antitumor Effects by Targeting Angiogenic Genes that Have Predictive Value for the Diagnosis, Prognosis and Recurrence of Hepatocellular …
  188. Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer
  189. Abstract LB-181: Piperlongumine inhibits growth and survival of human Burkitt lymphoma by downregulating NF-κB, c-Myc and LMP1
  190. Piperlongumine Induces Cell Cycle Arrest via Reactive Oxygen Species Accumulation and IKKβ Suppression in Human Breast Cancer Cells
  191. Repression of Hexokinases II-Mediated Glycolysis Contributes to Piperlongumine-Induced Tumor Suppression in Non-Small Cell Lung Cancer Cells
  192. Increased Expression of FosB through Reactive Oxygen Species Accumulation Functions as Pro-Apoptotic Protein in Piperlongumine Treated MCF7 Breast Cancer …
  193. Antimelanogenic activities of Piperlongumine derived from Piper longum on murine B16F10 melanoma cells in vitro and zebrafish embryos in vivo: its …
  194. Piperlongumine, a piper alkaloid targets Ras/PI3K/Akt/mTOR signaling axis to inhibit tumor cell growth and proliferation in DMH/DSS induced experimental …
  195. … , a Key Intermediate for Anti-Androgen Compounds, and Synthesis of 5, 6-dihydropyridine-2 (1H)-one, a Key Intermediate of Piperlongumine and its Derivatives
  196. Nanoparticle-encapsulated Piperlongumine modulates metastatic processes in triple-negative breast cancer cells
  197. 2517 Piperlongumine inhibits cell growth and triggers apoptosis via intrinsic pathway in prostate cancer cells
  198. Therapeutic Potential of Piperlongumine for Pancreatic Ductal Adenocarcinoma (PDAC)
  199. Piperlongumine 抑制 ABC 型弥漫大 B 细胞淋巴瘤细胞增殖的研究
  200. 천연물, 유기합성: Piperlongumine 유도체 합성과 Aflatoxin B1 생성 억제 효과
  201. Cancer-targeted pro-oxidant therapy using piperlongumine-loaded polypeptide micelles
  202. An investigation into the interaction between piplartine (piperlongumine) and human serum albumin
  203. 探討天然物 Piperlongumine 對 TNF-α 誘導 HeLa 細胞的發炎反應中 NF-κB p65 的影響
  204. Synthesis of Piperlongumine Derivatives Isolated from Piper longum L. and their Inhibitory Activity on Aflatoxin Production
  205. Effects of Piperlongumine Isolated from Piper longum L. on Platelet Aggregation and VSMC Proliferation
  206. C-2-1 The Structure of Piperlongumine, a Biogenetic Variant of Piperine (Alkaloids and alkaloid biosynthesis)
  207. P-070 (O-14) Piperlongumine が誘発する二本鎖 DNA 切断と染色体断裂 (ポスターセッション)
Related Posts

Magnolia Officinalis

Capparis Spinosa

Caffeic Acid

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping